Cervical Cancer Screening.
Katherine Gavinski, Deborah DiNardo
https://pubmed.ncbi.nlm.nih.gov/36759096Actively Recruiting
Age: 18Years - 90Years
FEMALE
ID06306170
Efficacy of Advanced Radiotherapy in Gynecological Cancer Patients
Led by IRCCS San Raffaele · Updated on 2025-04-22
1000
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting an observational study on patients with gynecologic cancers who have been treated with advanced radiotherapy techniques such as Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), and Stereotactic Body Radiotherapy (SBRT). The study aims to analyze toxicity levels and clinical outcomes including tumor control and survival rates. The study includes patients treated at the IRCCS San Raffaele Scientific Institute between January 2005 and January 2024. The study involves reviewing clinical and dosimetric data from these patients to assess acute and late treatment-related toxicities and to evaluate outcomes like local, regional, and distant control of the cancer, disease-free survival, cancer-specific survival, and overall survival. Researchers will also explore factors that may predict toxicity, disease progression, and survival, including radiomic characteristics from imaging. Participants' medical records and treatment details will be analyzed without any additional interventions. The primary measurements include survival without relapse or metastases over up to 120 months after radiotherapy completion, as well as acute toxicity within three months and late toxicity beyond three months after treatment. This long-term follow-up is intended to provide insights into the safety and effectiveness of advanced radiotherapy for gynecologic cancers.
CONDITIONS
Brief Title
Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)
Who Can Participate
Age: 18Years - 90Years
FEMALE
Eligibility Criteria
You may qualify if you...
- Gynecologic cancer patients
- Older than 18 years
- Treated with advanced radiotherapy techniques such as IGRT, IMRT, or SBRT
You will not qualify if you...
- Having other types of tumors
- Older than 90 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 120 months
Participants who underwent advanced radiotherapy for gynecological cancer are observed. Clinical and dosimetric data are retrieved and analyzed to evaluate outcomes and toxicity.
Visits and assessments occur as part of routine follow-up care over several years
Trial Site Locations
Total: 1 location
1
San Raffaele Scientific Institute
Milan, MI, Italy, 20132
Actively Recruiting
Loading map...
Research Team
A
Andrei Fodor, MD
N
Nadia G Di Muzio, Prof
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Ovarian Cancer: An Integrated Review.
Christine Stewart, Christine Ralyea, Suzy Lockwood
https://pubmed.ncbi.nlm.nih.gov/30867104Cancer statistics, 2022.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs...
https://pubmed.ncbi.nlm.nih.gov/35020204Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel...
https://pubmed.ncbi.nlm.nih.gov/33538338Endometrial cancer.
Vicky Makker, Helen MacKay, Isabelle Ray-Coquard...
https://pubmed.ncbi.nlm.nih.gov/34887451FIGO staging of endometrial cancer: 2023.
Jonathan S Berek, Xavier Matias-Guiu, Carien Creutzberg...
https://pubmed.ncbi.nlm.nih.gov/37337978Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma...
https://pubmed.ncbi.nlm.nih.gov/31908301ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.
N Colombo, C Creutzberg, F Amant...
https://pubmed.ncbi.nlm.nih.gov/26634381Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer.
Lucia Tortorella, Stefano Restaino, Gian Franco Zannoni...
https://pubmed.ncbi.nlm.nih.gov/33470061Nodal metastasis in gynecologic malignancies: Update on imaging and management.
Subramaniyan Ramanathan, Sree Harsha Tirumani, Vijayanadh Ojili
https://pubmed.ncbi.nlm.nih.gov/31821973